En español
NIDA

National Advisory Council Agenda

127th Meeting of the National Advisory Council on Drug Abuse

Neuroscience Center - Conference Rooms C & D
6001 Executive Boulevard, Bethesda, MD.

September 6, 2017

Closed Session

This meeting is closed to the public in accordance with the provisions set forth in section 552b{c} and 552b{c}(6), Title 5, U.S. Code and section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

9:00 a.m.

Call to Order
Nora Volkow, M.D. Director, NIDA

Review of Policy and Procedures
Susan Weiss, Ph.D.,
Executive Secretary,
National Advisory Council on Drug Abuse,
Director, Division of Extramural Research, NIDA

9:15 a.m.

Council Review of Grant Applications
Nora Volkow, M.D., Director, NIDA

Division of Epidemiology, Services, and Prevention Research (DESPR)
Carlos Blanco, M.D., Ph.D., Director

Division of Therapeutics and Medical Consequences (DTMC)
Ivan Montoya, M.P.H., M.D, Acting Director

Division of Neuroscience and Behavior (DNB)
Rita Valentino, Ph.D., Director

Office of Science Policy and Communications
Jack Stein, MSW, Ph.D., Director

10:15 a.m. Break

WebEx Information (Open Session Only)

Topic: WebEx - 127th Meeting, National Advisory Council on Drug Abuse
Date and Time: Wednesday, September 6, 2017 - 10:30 a.m. Eastern Daylight Time (New York, GMT-04:00), 7 hours
Meeting Number (Access Code):  291 558 598
Password: Success1

Add to Calendar  When it's time, start your meeting.

Join by phone

1-650-479-3208 Call-in toll number (US/Canada)

Important Notice:  Please note new WebEx policies provide a toll number for call-in. You can still use Calling using computer or “Call me” to ensure there are no charges. Additional Details below. 

WebEx Toll-Free Number Restriction Policy Reminder

Effective July 31, 2017, CIT has discontinued the use all WebEx toll-free phone numbers effective July 31, 2017. However, Call Using Computer option and the Call Me option will provide free calls within the United States and Canada. Long-distance charges may apply to international callers.

For more information about calling options, see the following descriptions:

Open Session

10:30 a.m. Welcome and Opening Remarks
Nora Volkow, M.D. Director, NIDA
10:35 a.m. Director's Report
Nora Volkow, M.D. Director, NIDA
11:30 p.m. Addressing the Opioid Epidemic through Public Private Partnerships for New Medications Development​
Francis Collins, M.D., Ph.D., Director, NIH
12:00 p.m. Follow up Discussion (Director’s Report)
12:45 p.m. Lunch Break (Steering Group Meeting)
2:15 p.m. Clinical Trials Stewardship Update: Policies and Definitions
Dr. Michael Lauer, Director, Office of Extramural Research, NIH
3:00 p.m. Update from the IRP​
Antonello Bonci, M.D., Scientific Director, Intramural Research Program, NIDA
3:40 p.m. Break
4:00 p.m. Concept Clearances​
NIDA Staff
4:30 p.m. Public Comments
4:45 p.m. Adjourn

This page was last updated August 2017